Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type

Kim, Jiyoung; Kim, Jee Ye; Lee, Han‐Byoel; Lee, Young Joo; Seong, Min-Ki; Paik, Nam-Sun; Park, Woo-Chan; Park, Sung Min; Jung, Seung Pil; Bae, Soo Youn

doi:10.1007/s10549-020-05861-6

Cited by 31 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Leon et al in 2018 and Kim et al in 2020 found 70.0% and 86.0% of invasive carcinoma (NST) cases in their study respectively. 15,16 In present study, out of 205 cases of Invasive Carcinoma NST, most common tumor histological grade seen was grade 2 (moderately differentiated carcinoma) in 102(49.9%) cases followed by grade 3 (poorly differentiated) in 61(29.9%) cases and grade 1 (well differentiated carcinoma) in 41(20.2%) cases. Unlu et al in 2017 and Oddo et al in 2018 showed grade 2 was the most common histologic grade (49.0% & 45.3%) followed by grade 3(35.1% & 42.1% respectively).…”

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Is CD 44 really a marker of breast cancer metastasis or is nefarious in its nature

Warsi¹,

Akhtar²,

Rab³

2021

ACHR

View full text Add to dashboard Cite

To study the expression of immunomarker CD 44 and evaluate its diagnostic and prognostic significance and its correlation with clinicopathological variables in Breast Carcinoma. Materials and Methods: 50 diagnosed cases of breast carcinoma, presenting clinically with breast lumps were processed routinely for histopathological diagnosis of breast cancer and immunoexpression of CD 44 was performed. The immunoexpression of CD44 was detected mainly at the membrane of tumour cells and the scoring was performed. Results: 217 (98.2%) were females and 4(1.8%) males. Most common subtype involved was invasive carcinoma (NST) in 205(92.8%) cases. Out of 29 cases of grade 2 tumor, 07 (14.0%) showed 1+ score, 10 (20.0 %) showed 2+ score and 12 (24.0%) cases showed 3+ immunoexpression. Out of 25 cases of T2 (2-5 cm) size, 07(14.0%) showed 1+ score, 09(18.0%) case each showed 2+ score and 3+ immunoexpression. Out of 26 cases of stage III, 04(8.0%) showed 1+ score, 09(18.0%) showed 2+ score and 13(26.0%) cases showed 3+ immunoexpression. Out of 05 cases of N3, 02(4.0%) showed 2+ score and 03(6.0%) showed 3+ immunoexpression. Out of 21 cases of basal cell type, 03(6.0%) showed 1+ score, 07(14.0 %) showed 2+ score and 11(22.0%) cases showed 3+ immunoexpression. Out of 11 (50.0%) cases with weak to moderate expression of CD44, 7(31.8%) cases were stable and alive while 4(18.2%) died due to distant metastasis to various sites. Conclusions: CD 44 is associated with disease progression, recurrence, advanced metastasis and reduced disease free survival and can be used in future to predict early diagnosis of advanced disease.

show abstract

Section: Discussionmentioning

confidence: 50%

“…27 Kim et al in 2020 showed that CD44 expression affected prognosis predominantly in the receptor negative study group and correlated with favourable prognosis. 16…”

Section: Discussionmentioning

confidence: 99%

Is CD 44 really a marker of breast cancer metastasis or is nefarious in its nature

Warsi¹,

Akhtar²,

Rab³

2021

ACHR

View full text Add to dashboard Cite

show abstract

“…Breast cancer is one of the most prevailing types of cancer, with an incidence of 128.5 per 100,000 woman per year [ 112 ]. The most common histopathological subtype, accounting for 75% of all breast cancers, is invasive carcinoma of no special type (IC-NST), formerly known as invasive ductal carcinoma [ 113 ]. The second most common type is invasive lobular carcinoma (ILC) (5–10%).…”

Section: Resultsmentioning

confidence: 99%

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Uijen¹,

Derks

Merkx³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [177Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.

show abstract

“…However, recent studies and meta-analyses seem to suggest that there is no tangible difference in disease-free survival, recurrence-free survival, or overall prognosis. 23 , 58 , 142–145 One such meta-analysis, that utilizes a great number of previous prognostic comparative studies, is the one by Hao et al 44 After a meticulous process of balancing key characteristics of the two populations (age, lymph nodes, grade, stage), the analysis demonstrated no statistically significant difference in overall survival and disease-free survival between patients with IMPC and those with IDC. Additionally, they demonstrated that the micropapillary subtype did not carry any gravity as an independent prognostic factor.…”

Section: Lymphovascular Invasion and Lymph Node Involvementmentioning

confidence: 99%

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

GI¹,

Tchabashvili²,

Mulita³

et al. 2022

BCTT

View full text Add to dashboard Cite

Invasive micropapillary carcinoma (IMPC) of the breast is an infrequent type of breast cancer often discussed for its potency for lymphovascular invasion and difficulty in accurate imaging estimation. Micropapillary carcinomas are noted to be present as larger tumors, of higher histological grade and a notably higher percentage of disease-positive lymph nodes. Hormonal and HER-2 positivity in IMPC is also commoner when compared to other NST carcinomas. IMPC occurs either as a pure form or more often as a component of mixed Non-Specific Type (NST) carcinoma. The latest data suggest that despite having comparable survival rates to other histological subtypes of breast carcinoma, effective surgical treatment often requires extended surgical margins and vigilant preoperative axillary staging due to an increased incidence of lymph node invasion, and locoregional recurrence. Moreover, the presence of micropapillary in situ components within tumors also seems to alter tumor aggression and influence the nodal disease stage. In this review, we present an overview of the current literature of micropapillary carcinoma of the breast from biology to prognosis, focusing on biological differences and treatment.

show abstract

Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type

Cited by 31 publications

References 43 publications

Is CD 44 really a marker of breast cancer metastasis or is nefarious in its nature

Is CD 44 really a marker of breast cancer metastasis or is nefarious in its nature

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

Contact Info

Product

Resources

About